Pembrolizumab Approved in Metastatic Small Cell Lung Cancer

Pembrolizumab (Keytruda®, Merck) has received accelerated FDA approval for patients with metastatic small cell lung cancer (SCLC) experiencing disease progression during or after platinum-based chemotherapy following at least one other previous line of therapy. Metastatic SCLC, or extensive-stage SCLC, comprises around 15% of all lung cancers and occurs primarily in heavy smokers. It carries a dismal outlook; only 5% of patients with extensive-stage SCLC live for two years after diagnosis. Appro...
Continue reading

Cancer Immunotherapy Collaborative Learning With Latha Shivakumar, PhD, CHCP

​ In the constantly evolving field of cancer immunotherapy, it is crucial that community practitioners keep abreast of the latest advances. In this interview with i3 Health, Latha Shivakumar, PhD, CHCP, discusses her poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting concerning the initiative she led at the Association of Community Cancer Centers (ACCC): collaborative learning workshops focused on best practices for immunotherapy in the community setting. What...
Continue reading

I-SNAP: Immunotherapy Standardized Nursing Assessment Protocol With Keri Mahoney, JD, RN, CPHRM

With the rapidly increasing use of immunotherapy in the treatment of some cancers, oncology nurses need to be comfortable and knowledgeable in administering immunotherapeutic treatments and assessing patients for immune-related adverse events. In this interview with i3 Health, Keri Mahoney, JD, RN, CPHRM, discusses her immunotherapy educational intervention for nurses, which she presented in a poster at the Oncology Nursing Society (ONS) 44th Annual Congress in Anaheim, California. What was the ...
Continue reading

Preparing Nurses to Manage CAR T-Cell Therapy Adverse Events With Lindsey Bashaw, RN

Chimeric antigen receptor (CAR) T-cell therapy is a new form of immunotherapy in which a patient's own T cells are collected and genetically altered to target cancer cells. Although CAR T-cell therapy has shown encouraging clinical trial results in patients with acute lymphoblastic leukemia and B-cell lymphomas, they are associated with severe adverse events such as cytokine release syndrome, neurotoxicity, tumor lysis syndrome, and graft-versus-host disease. Many of the patients who receive CAR...
Continue reading

New Insights into the Precise Function of CAR T Cells

​ Chimeric antigen receptor (CAR) T-cell therapy modifies the patient's own T cells, otherwise known as natural killer cells or cytotoxic T lymphocytes, to enable the T cells to recognize and eliminate a target molecule, CD19, on the cancerous cells. While this form of immunotherapy has great potential in treating B-cell malignancies, relapse does occur in some patients. Researchers have gained new insights into the outcome and dynamics of CAR T-cell interactions in different anatomical sites, r...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.